1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,800 | 7,000 | 28.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.06. | Terns Pharmaceuticals, Inc.: Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201 | - | GlobeNewswire (USA) | ||
| 14.06. | Terns Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.06. | Lilly-backed Terns tees up combo trial as oral NASH drug shows promise in phase 2 | 2 | FierceBiotech | ||
| TERNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 14.06. | Terns Pharmaceuticals touts safety data from an ex-Eli Lilly candidate in the hunt for NASH treatment | 4 | Endpoints News | ||
| 14.06. | Terns Pharmaceuticals up 9% on positive phase 2 NASH data | 1 | Seeking Alpha | ||
| 14.06. | Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study | - | Seeking Alpha | ||
| 14.06. | Terns Pharmaceuticals, Inc.: Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH | 1 | GlobeNewswire (USA) | ||
| 13.06. | Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment ... | 1 | GlobeNewswire (USA) | ||
| 07.04. | Terns Pharmaceuticals, Inc.: Terns to Present at the 19th Annual Virtual Needham HealthCare Conference | 1 | GlobeNewswire (USA) | ||
| 06.04. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 06.04.2021 | 507 | Xetra Newsboard | The following instruments on XETRA do have their first trading 06.04.2021 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am 06.04.2021
Aktien
1 US6612041078 North Mountain Merger... ► Artikel lesen | |
| 30.03. | Terns Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.03. | Terns Pharmaceuticals reports Q4 results | 3 | Seeking Alpha | ||
| 30.03. | Terns Pharmaceuticals, Inc.: Terns Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update | 1 | GlobeNewswire (USA) | ||
| 26.03. | The Promises Behind Terns' Multi-Pronged Pipeline | - | The Motley Fool | ||
| 22.03. | Terns Pharmaceuticals, Inc.: Terns Announces Initiation of Dosing in Phase 1 Clinical Trial of TERN-501, its THR-Beta Agonist in Development for the Treatment ... | 1 | GlobeNewswire (USA) | ||
| 23.02. | Terns Pharmaceuticals, Inc.: Terns to Present at the Cowen 41st Annual Health Care Conference | - | GlobeNewswire (USA) | ||
| 10.02. | Terns Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares | 2 | GlobeNewswire (USA) | ||
| 09.02. | Terns Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.02. | NASH biotech Terns Pharmaceuticals opened at $16.95, below IPO price of $17 | 4 | Seeking Alpha | ||
| 05.02. | NASH biotech Terns Pharmaceuticals prices upsized IPO at $17 high end | 1 | Renaissance Capital |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 3,965 | -1,49 % | wikifolio whispers p.m. zu Medigene, Steinhoff, SLM Solutions ... | Medigene -3.48% bwarnebold (19195625): Die Privatbank Berenberg hat Medigene mit "Buy" und einem Kursziel von 8 Euro in die Bewertung aufgenommen. Die vom Biotech-Unternehmen entwickelten T-Zell-Therapien... ► Artikel lesen | |
| BIOFRONTERA | 2,750 | -4,18 % | Biotech Report: BioFrontera und Evotec legen zu; Biogen nach Zahlen | (shareribs.com) Frankfurt / New York 23.07.2021 - Biotech-Werte zeigen sich im deutschen Handel überwiegend fester. Unter anderem können BioFrontera und Evotec zulegen, auch MorphoSys klettern. Biogen... ► Artikel lesen | |
| 4SC | 6,090 | +0,33 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.07.2021 | Das Instrument LDF DE000A2QRHL6 LINUS DIGITAL FINANCE AG EQUITY hat seinen ersten Handelstag am 19.07.2021: CONTINUOUS TRADING WITH AUCTIONS, PAG GER0, SettlCurr EUR, CCP Y
The instrument LDF DE000A2QRHL6... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,428 | +1,18 % | EARNINGS SUMMARY: Details of Palatin Technologies Inc. Q3 Earnings Report | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Palatin Technologies Inc. (PTN):-Earnings: -$5.7 million in Q3 vs. -$5.4 million in the same period last year.
-EPS: -$0.02 in... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 7,290 | +4,26 % | Is Inovio Pharmaceuticals Primed For a Comeback? | ||
| SANGAMO THERAPEUTICS | 8,476 | +4,44 % | Sangamo Therapeutics, Inc.: Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) released details supporting... ► Artikel lesen | |
| HEAT BIOLOGICS | 5,560 | +4,12 % | Heat Biologics, Inc.: Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021 | DURHAM, NC / ACCESSWIRE / April 12, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system... ► Artikel lesen | |
| INFLARX | 2,178 | +4,01 % | InflaRx: Phase-II-Studie mit Vilobelimab gestartet | Das Jenaer Biotech-Unternehmen InflaRx ist in die "heiße Phase" einer klinischen Studie mit dem Medkamentenkandidaten Vilobelimab gestartet. In die Phase-II-Studie sei nun der erste Patient aufgenommen... ► Artikel lesen | |
| AETERNA ZENTARIS | 0,664 | +3,75 % | TUI, Heidelberg Pharma, Endeavour Silver, First Majestic Silver, 3D Systems, Aeterna Zentaris, ... | Unsere Trading-Tipps sind so angelegt, dass wir Verluste möglichst vermeiden oder sie bei einer unvorhersehbaren Trendwende mindestens so gering wie möglich halten wollen. Nichts verlieren und auch... ► Artikel lesen | |
| IBIO | 1,080 | +3,35 % | iBio says successful in preclinical studies for subunit COVID-19 vaccine candidate | ||
| BELLEROPHON THERAPEUTICS | 3,540 | +0,43 % | Why Entera Bio, Orphazyme, Bellerophon Are Moving Today | ||
| REDHILL BIOPHARMA | 5,560 | +4,12 % | RedHill Biopharma Ltd: RedHill Settles Movantik Apotex Patent Litigation | RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with ApotexTEL AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / July 22, 2021 / RedHill Biopharma Ltd. (Nasdaq:RDHL) ('RedHill' or the... ► Artikel lesen | |
| EVOLVA | 0,169 | +1,87 % | Evolva sichert sich weiteres Kapital | Reinach (awp) - Das Biopharmaunternehmen Evolva hat sich weitere finanzielle Mittel gesichert. So wird die Investmentgesellschaft Nice Green in Form einer Wandelanleihe bis Ende 2022 maximal 20 Millionen... ► Artikel lesen | |
| VAXART | 6,838 | +0,41 % | Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards? | ||
| BIOMARIN PHARMACEUTICAL | 66,44 | +0,21 % | EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q2 Earnings Report | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Biomarin Pharmaceutical Inc. (BMRN):-Earnings: $12.9 million in Q2 vs. -$29.2 million in the same period last year.
-EPS: $0.07... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
